National HealthCare (NHC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- —
- Surprise
- —
- Revenue (period 2026-06-30)
- $408.0M
- Score today
- 5.0/10
Revenue source: xbrl.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NHC Sell at 5.0/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-06.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Earnings expected to decline ~95% (cyclical peak)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4)
- Consecutive earnings misses (4)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $219.60
- Price target
- $243.24
- Stop
- $210.72
- Upside to target
- +10.8%
Forward estimates sit below the trailing run-rate (520.2× forward vs 25.2× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
NHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $3.50B
- P/E (fwd)
- 520.2
- P/E (ttm)
- 25.2
- 52-week range
- $118.14–$248.20
- Off 52-week high
- 11.5%
- RSI (14)
- 49
- Volume vs avg
- 0.32×
- Score today
- 5.0/10